Rachel Kobos

7.8k total citations
65 papers, 830 citations indexed

About

Rachel Kobos is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Rachel Kobos has authored 65 papers receiving a total of 830 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hematology, 33 papers in Oncology and 12 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Rachel Kobos's work include Multiple Myeloma Research and Treatments (27 papers), CAR-T cell therapy research (16 papers) and Acute Lymphoblastic Leukemia research (11 papers). Rachel Kobos is often cited by papers focused on Multiple Myeloma Research and Treatments (27 papers), CAR-T cell therapy research (16 papers) and Acute Lymphoblastic Leukemia research (11 papers). Rachel Kobos collaborates with scholars based in United States, Spain and France. Rachel Kobos's co-authors include Neerav Shukla, Peter G. Steinherz, Ajay K. Nooka, María‐Victoria Mateos, Susan E. Prockop, Michael P. LaQuaglia, Nancy A. Kernan, Andromachi Scaradavou, Farid Boulad and Thomas Renaud and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Rachel Kobos

60 papers receiving 815 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachel Kobos United States	18	445	359	315	98	97	65	830
Axel Schulenburg Austria	18	511 1.1×	337 0.9×	235 0.7×	216 2.2×	94 1.0×	41	990
Sharmilan Thanendrarajan United States	19	657 1.5×	526 1.5×	469 1.5×	172 1.8×	48 0.5×	110	1.0k
Neil Kogut United States	18	352 0.8×	495 1.4×	111 0.4×	135 1.4×	55 0.6×	52	914
Martin Dreyling Germany	18	406 0.9×	400 1.1×	292 0.9×	89 0.9×	55 0.6×	63	938
Benoît Tessoulin France	18	365 0.8×	516 1.4×	436 1.4×	219 2.2×	76 0.8×	79	1.2k
Anna van Rhenen Netherlands	13	696 1.6×	408 1.1×	404 1.3×	300 3.1×	43 0.4×	39	1.2k
Mariko Ishibashi Japan	13	309 0.7×	322 0.9×	297 0.9×	282 2.9×	42 0.4×	36	748
Shih‐Feng Cho Taiwan	20	561 1.3×	674 1.9×	530 1.7×	268 2.7×	114 1.2×	70	1.3k
Karen Silence Belgium	15	266 0.6×	299 0.8×	328 1.0×	368 3.8×	131 1.4×	26	1000
A. John Ashcroft United Kingdom	16	949 2.1×	913 2.5×	663 2.1×	190 1.9×	71 0.7×	23	1.5k

Countries citing papers authored by Rachel Kobos

Since Specialization

Citations

This map shows the geographic impact of Rachel Kobos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Kobos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Kobos more than expected).

Fields of papers citing papers by Rachel Kobos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Kobos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Kobos. The network helps show where Rachel Kobos may publish in the future.

Co-authorship network of co-authors of Rachel Kobos

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Kobos. A scholar is included among the top collaborators of Rachel Kobos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Kobos. Rachel Kobos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kobos, Rachel, et al.. (2024). Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study. Seminars in Oncology Nursing. 40(3). 151621–151621. 2 indexed citations

Nooka, Ajay K., Cesar Rodriguez, María‐Victoria Mateos, et al.. (2023). Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study. Cancer. 130(6). 886–900. 36 indexed citations

Martin, Thomas G, María‐Victoria Mateos, Ajay K. Nooka, et al.. (2023). Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma. Cancer. 129(13). 2035–2046. 28 indexed citations

Manier, Salomon, Ajay K. Nooka, Cesar Rodriguez, et al.. (2023). MM-192 Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S480–S481.

Krishnan, Amrita, Ajay K. Nooka, Ajai Chari, et al.. (2023). Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. Journal of Comparative Effectiveness Research. 12(6). e220186–e220186. 8 indexed citations

Mateos, María‐Victoria, Pieter Sonneveld, Vânia Hungria, et al.. (2019). Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clinical Lymphoma Myeloma & Leukemia. 20(8). 509–518. 93 indexed citations

Weisel, Katja, Pieter Sonneveld, María‐Victoria Mateos, et al.. (2019). Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor. Blood. 134(Supplement_1). 3192–3192. 26 indexed citations

Kaufman, Jonathan L., Saad Z. Usmani, Jesús F. San Miguel, et al.. (2019). Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 134(Supplement_1). 1866–1866. 28 indexed citations

Ortiz, Michael V., Kavitha Ramaswamy, Christopher J. Forlenza, et al.. (2018). Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis. Pediatric Blood & Cancer. 66(1). e27500–e27500. 5 indexed citations

10.

Anur, Pavana, Danielle Novetsky Friedman, Charles A. Sklar, et al.. (2016). Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors. Bone Marrow Transplantation. 51(7). 938–944. 31 indexed citations

11.

Spitzer, Barbara, Miguel‐Angel Perales, Nancy A. Kernan, et al.. (2016). Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. Biology of Blood and Marrow Transplantation. 22(8). 1449–1454. 10 indexed citations

12.

Darcy, David G., Marcus M. Malek, Rachel Kobos, et al.. (2014). Prognostic factors in fibrolamellar hepatocellular carcinoma in young people. Journal of Pediatric Surgery. 50(1). 153–156. 50 indexed citations

13.

Kobos, Rachel, Makoto Nagai, Masumi Tsuda, et al.. (2013). Combining integrated genomics and functional genomics to dissect the biology of a cancer‐associated, aberrant transcription factor, the ASPSCR1–TFE3 fusion oncoprotein. The Journal of Pathology. 229(5). 743–754. 50 indexed citations

14.

Kobos, Rachel, Neerav Shukla, Thomas Renaud, et al.. (2013). High-Dose Cyclophosphamide for the Treatment of Refractory T-Cell Acute Lymphoblastic Leukemia in Children. Journal of Pediatric Hematology/Oncology. 36(5). e265–e270. 6 indexed citations

15.

Honeyman, Joshua N., Barrie S. Rich, Maureen McEvoy, et al.. (2012). Factors associated with relapse and survival in Wilms tumor: a multivariate analysis. Journal of Pediatric Surgery. 47(6). 1228–1233. 22 indexed citations

16.

Chou, Joanne F., Nancy A. Kernan, Susan E. Prockop, et al.. (2011). Safety and Immunogenicity of the Live Attenuated Varicella Vaccine Following T Replete or T Cell-Depleted Related and Unrelated Allogeneic Hematopoietic Cell Transplantation (alloHCT). Biology of Blood and Marrow Transplantation. 17(11). 1708–1713. 34 indexed citations

17.

Curran, Kevin J., Nancy A. Kernan, Susan E. Prockop, et al.. (2011). Paroxysmal nocturnal hemoglobinuria in pediatric patients. Pediatric Blood & Cancer. 59(3). 525–529. 31 indexed citations

18.

Kobos, Rachel, Peter G. Steinherz, Nancy A. Kernan, et al.. (2011). Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Patients with Treatment-Related Myelodysplastic Syndrome or Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation. 18(3). 473–480. 19 indexed citations

19.

Steinherz, Peter G., Neerav Shukla, Rachel Kobos, & Sheron Latcha. (2010). Effect of hemodialysis on the plasma levels of clofarabine. Pediatric Blood & Cancer. 55(1). 196–198. 3 indexed citations

20.

Steinherz, Peter G., Neerav Shukla, Rachel Kobos, & Laurel J. Steinherz. (2010). Remission re‐induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatric Blood & Cancer. 54(5). 687–693. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact